ClinicalTrials.gg
RecruitingNCT06513286TherVacBUpdated Jun 11, 2026

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

A Phase 1/2 interventional study of TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac) and TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac) in Chronic Hepatitis B, sponsored by Michael Hoelscher. Recruiting at 6 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Michael Hoelscher · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Hepatitis B, Chronic with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · Germany.

Planned enrollment
31st of 44
81 · median 137
Started
2025
the only one that year
Phase 1/2
2 of 53
1 open now
Registered
52nd of 53
by date

Among the 53 studies in Hepatitis B, Chronic with a site in Germany, this one is the 31st largest by planned enrollment of the 44 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 52nd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 53 studies in Hepatitis B, Chronic with a site in Germany is open now.

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hepatitis B, Chronic with a site in Germany, or all of them as a file.
02

Study summary

This study is an open-label, ascending dose phase 1b/2a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.

Read the detailed description

This is a multi-centre study conducted in 81 participants. The clinical trial is divided into two overlapping parts (part A and B).

All treatment groups of Part A will receive a single dose of HEPLISAV B on Day 1 and Day 29 and MVA-HBVac on Day 56. From study arm A2 on all participants also receive HBcoreAg, in a low dose in arms A2 and A3 and in a medium dose in arm A4. In arms A5 and A6 either the low or the medium dose will be applied to an extended number of participants. The MVA-HBVac booster dose will be given in a dose-escalating way with a low dose in arms A1 and A2 and a high dose in arms A3, A4, A5 and A6.

The treatment group in Part B, study arm B1 will receive two doses of HEPLISAV B together with HBcoreAg in a high dose (on day 1 and 29), and a high booster dose of MVA-HBVac on day 56. In arm B2 either the regimen of B1 or A5 will be applied to an extended number of participants.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the subject information and to personally name, sign and date the to participate in the clinical trial.
  2. Provided written informed consent.
  3. Confirmed chronic virus (HBV) infection (CHB) that fulfills the following criteria:

    • HBsAg positive for ≥ 6 months
    • Anti-HBs negative
    • HBsAg levels 100-2000 IU/mL
    • HBV nucleos(t)ide analog (NUC) treatment for ≥ 6 months
    • HBV load \< 100 IU/ml at least twice within the last 6 months
  4. Males and non-pregnant, non-lactating female with negative pregnancy test aged 18-70 years at time of informed consent.
  5. Apart from CHB no other health problems as determined during medical history and physical examination and clinical laboratory results at the screening visit. The following abnormal laboratory parameters will be permitted:

    • leukocyte count ≥ 2.500/µl
    • count ≥ 150.000/µl
    • elevation ≤ 60 U/L
    • AST should be ≤ 40 U/L
    • should be ≤
    • should be ≤ ULN
    • CrCL > 60mL/min Non-clinically significant, minor deviations of laboratory measurements can be tolerated as they will not increase the risk of the individual having an adverse outcome from participating in this clinical trial as judged by the investigator.
  6. Subject may be on chronic or as needed medications if, in the opinion of the investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate worsening of a pre-existing medical condition.
  7. 18.5-32.0 kg/m2 and weight >50 kg at screening.

Exclusion criteria

Exclusion Criteria:

  1. Known liver disease other than
  2. Advanced liver fibrosis or cirrhosis (demonstrated by ultrasound or transient elastography ≥8 kP in fasting condition)
  3. who don't agree to comply with the applicable requirements of the protocol
  4. History of hepatocellular carcinoma
  5. Coinfection with Virus (HCV) (RNA positive), (HIV) or Hepatitis Delta virus (anti-Delta positive)
  6. Regular alcohol intake >30 g/d (male), >20 g/d (female) or any other known drug addiction.
  7. Donation of blood or blood products (e.g., 450 mL or more of plasma or ) within 60 days prior to receiving the first dose of the medicinal product (IMP).
  8. Receipt of any vaccine in the 2 weeks prior to first trial vaccination (4 weeks for ), during trial or planned receipt of any vaccine in the 3 weeks following last trial vaccination. Exception: Required recommended pandemic vaccines or emergency vaccines (e.g., tetanus) are allowed.
  9. Previous receipt of an MVA based vaccine (e.g. as part of previous MVA studies, monkeypox or smallpox vaccination)
  10. Known allergy to components of the vaccine products as referred in Table 6 (incl. to yeast components, E.coli proteins or lipids, duck's or hen's egg white, penicillin, streptomycin, , kanamycin) or history of life-threatening reactions to vaccines containing one of the substances.
  11. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccines.
  12. findings in or significant thromboembolic events in medical history.
  13. Evidence for a condition in the subject's medical history or during medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of vaccine products.
  14. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the first dose of the trial vaccine.
  15. Any confirmed or suspected or immunodeficient condition, cytotoxic therapy in the previous 3 years.
  16. Any treatment with immunosuppressants or other immune-modifying drugs (including, but not limited to systemic , biologicals and Methotrexate) within the last 3 years. Exception: topical corticosteroids, e.g. occasional asthma spays or systemic corticosteroids for medical emergencies.
  17. Any chronic or active neurologic disorder, including diagnosis of migraine, seizures and epilepsy. Exception: a febrile seizure as a child and occasional headaches.
  18. Participation in a clinical investigation within the past 4 weeks or five times the half-life of the previously taken IMP.
  19. Investigator or employee of the study site with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study.
  20. Subjects who are known or suspected

    • not to comply with the clinical trial directives.
    • not to be reliable or trustworthy.
    • not to be capable of understanding and evaluating the information given to them as part of the formal information policy (), in particular regarding the risks and discomfort to which they would agree to be exposed.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    Arm A1

    HEPLISAV B® (low dose) and MVA-HBVac (low dose)

    Biological: TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

  • Experimental
    Arm A2

    HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (low dose)

    Biological: TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

  • Experimental
    Arm A3

    HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (high dose)

    Biological: TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

  • Experimental
    Arm A4

    HEPLISAV B® (low dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose)

    Biological: TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

  • Experimental
    Arm A5 (Europe)

    HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (high dose) or HEPLISAV B® (low dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose)

    Biological: TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

  • Experimental
    Arm A6 (Tanzania)

    HEPLISAV B® (low dose) \& HBcoreAg (low dose) and MVA-HBVac (high dose) or HEPLISAV B® (low dose) \& HBcoreAg (medium dose) and MVA-HBVac (high dose)

    Biological: TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

  • Experimental
    Arm B1

    HEPLISAV B® (high dose) \& HBcoreAg (high dose) and MVA-HBVac (high dose)

    Biological: TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)

  • Experimental
    Arm B2

    HEPLISAV B® (high dose) \& HBcoreAg (high dose) and MVA-HBVac (high dose) or regimen of study arm A5

    Biological: TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)

Interventions

  • BiologicalTherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

    Administration of the described combinations via the intramuscular route

  • BiologicalTherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)

    Administration of the described combinations via the intramuscular route

06

What researchers measure

Primary outcomes

  1. Frequencies and magnitudes of unsolicited adverse events

    Reported numbers and severity grade of unsolicited AEs for 28 days after each vaccination

    Time frame: up to day 84

  2. Frequencies and magnitudes of serious adverse events (SAEs) throughout the trial period

    Reported numbers and types of SAEs throughout the period of the clinical trial

    Time frame: up to day 224

  3. Frequencies and magnitudes of adverse event of special interest (AESI) and Suspected Unexpected Serious Adverse Reaction (SUSAR) throughout the trial period

    Reported numbers and severity grade of AESIs and numbers and types of SUSARs

    Time frame: up to day 224

  4. Frequencies and magnitudes of solicited local reactogenicity signs and symptoms within 7 days after each vaccination

    Reported numbers and severity of solicited AEs

    Time frame: up to day 63

  5. Frequencies and magnitudes of solicited systemic reactogenicity signs and symptoms within 7 days after each vaccination

    Reported numbers and severity of solicited AEs

    Time frame: up to day 63

  6. Frequencies and magnitudes of liver toxicity (ALT flare-ups) stratified by severity throughout the trial period

    Reported numbers and severity grade of AESIs

    Time frame: up to day 224

  7. Change from baseline of safety laboratory measurements throughout the trial period

    Changes of values from safety laboratory measurements from baseline

    Time frame: up to day 224

Secondary outcomes

  1. Frequency of subjects with HBsAg drop below the lower limit of quantification

    Determined by an accredited serological immuno-assay

    Time frame: 2 weeks (Day 70), 2 months (Day 112) and 6 months (Day 224) after completion of the vaccination regimen (last study visit).

  2. Frequency of subjects with a ≥ 1 log10 drop in HBsAg titers from day 0 (start of study medication) with the goal of 30% of patients achieving a ≥ 1log10 HBsAg drop

    Determined by an accredited serological immuno-assay

    Time frame: 2 weeks (Day 70), 2 months (Day 112) and 6 months (Day 224) after completion of the vaccination regimen (last study visit

  3. Frequency of subjects with an induction of anti-HBs titers ≥ 10 IU/L

    Determined by an accredited serological immuno-assay

    Time frame: 2 weeks (Day 70), 2 months (Day 112) and 6 months (Day 224) after completion of the vaccination regimen (last study visit

  4. Frequency of subjects developing any anti-HBs antibody response

    Determined by an accredited serological immuno-assay

    Time frame: 2 weeks (Day 70), 2 months (Day 112) and 6 months (Day 224) after completion of the vaccination regimen (last study visit

  5. Frequency of subjects with an increased signal in the HBV-specific cytokine-secretion assay compared to pretreatment values

    Determined by cytokine release assays

    Time frame: 2 weeks (Day 70), 2 months (Day 112) and 6 months (Day 224) after completion of the vaccination regimen (last study visit

07

Study locations

5 of 6 sites recruiting
  • Investigational Site GUF
    Frankfurt, 60590, Germany
    Recruiting
  • Investigational Site UKE
    Hamburg, 20246, Germany
    Recruiting
  • Investigational Site MHH
    Hanover, 30625, Germany
    Not yet recruiting
  • Investigational Site Uni Leipzig
    Leipzig, 04103, Germany
    Recruiting
  • Investigational Site LMU
    Munich, 81337, Germany
    Recruiting
  • Investigational Site TUM
    Munich, 81675, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD sharing plan is in preparation

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jul 22, 2024
StartActual
Jun 12, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06513286
Lead sponsor
Michael Hoelscher
Collaborators
Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany
Responsible party
Michael Hoelscher (Professor Dr. M. Hoelscher, Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Jul 22, 2024
Start date
Jun 12, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Otto Geisenberger, Dr.rer.nat.
Contact
otto.geisenberger@med.uni-muenchen.de
+49-89-4400598 ext. -26
Michael Hoelscher, Prof. Dr. med.
study chair · Division of Infectious Diseases and Tropical Medicine, LMU Klinikum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion